biOasis Technologies Ord Shs V.BTI.H

Attralus buys in brain shuttle tech to cross BBB

[LOOPA441]

Attralus makes deal with Ossianix (a BBB competitor).

https://www.globenewswire.com/news-release/2022/11/17/2558010/0/en/Attralus-and-Ossianix-Announce-an-Option-and-License-Agreement-using-the-TXP1-Brain-Shuttle-for-Targeted-Delivery-of-AT-04-a-Pan-Amyloid-Removal-Therapeutic-for-Neurodegenerative-D.html

LFG!

[JDavenport]

These transferrin receptor-based BBB transport technologies are getting quite numerous. In addition to Denali, there are   JCR Pharmaceuticals, and Ossianix, the one in the deal with Attralus  that LOOPA441 posted earlier.   They all use different technologies to deliver drugs across the BBB but all of their technologies use the same receptor, the transferrin receptor

[JDavenport]

I misspoke a little about other technologies not using the LRP-1 receptor. Angiochem's Angiopep-2 uses that receptor but, if I recall correctly, Angiopep-2 has difficulty decoupling from the LRP-1 receptor in the endosome, preventing the LRP-1 receptor from recycling back to the BBB endothelial cell surface. xB3-drugs, on the other hand, decouple easily from the LRP-1 receptor, allowing the